CureVac files for Nasdaq IPO to fund COVID-19 vaccine development 13-Aug-2020 By Nick Taylor CureVac files to raise upward of $200 million in Nasdaq IPO to fund clinical development of COVID-19 vaccine.
Moderna lands US COVID-19 vaccine contract worth up to $8bn 13-Aug-2020 By Nick Taylor US government inks deal to buy 100 million COVID-19 vaccine doses from Moderna for $1.5 billion, with more to follow.
Ligand inks $438m Pfenex buyout to add protein expression tech to portfolio 13-Aug-2020 By Nick Taylor Ligand Pharmaceuticals strikes deal to buy Pfenex for $438 million upfront in cash to gain control of protein expression technology.
Gates Foundation commits $150m to make COVID-19 vaccines for $3 a dose 11-Aug-2020 By Nick Taylor The Bill & Melinda Gates Foundation provides $150 million for production of $3 doses of COVID-19 vaccines.
COVID-19 drives 20% growth at Merck KGaA’s process solutions unit 11-Aug-2020 By Nick Taylor Rising demand for single-use and downstream products from developers of COVID-19 therapies and vaccines drives growth at Merck KGaA.
Moderna makes commercial case for COVID-19 vaccine amid price pressure 10-Aug-2020 By Nick Taylor Moderna Therapeutics reveals it is selling its COVID-19 vaccine for up to $37 a dose, well above the amount charged by some of its rivals.
Fate touts potential to make 15,000 cell therapy doses per cGMP run 10-Aug-2020 By Nick Taylor Fate Therapeutics touts potential to make cell therapies from renewable cell lines at scale after early production success.
Sanofi wins race to ship vaccines ahead of ‘record’ flu season 06-Aug-2020 By Nick Taylor Sanofi ships first influenza vaccines to US for 2020-2021 flu season that is tipped to generate record sales.
Emergent in $174m deal with AZ to expand manufacturing commitment 04-Aug-2020 By Ben Hargreaves Emergent will produce commercial scale drug substance for AZ’s potential vaccine for COVID-19.
Takeda sees ‘clear path’ to resolution of FDA warning letter 04-Aug-2020 By Nick Taylor Takeda aims to have the plant that manufactures drugs including Entyvio and leuprorelin ready for re-inspection within 12 months.
US government secures 100m doses of GSK and Sanofi vaccine for $2.1bn 03-Aug-2020 By Ben Hargreaves In return for capital for development and manufacturing scale-up help, Sanofi and GSK agree number of doses of potential COVID-19 vaccine.
Kite gets second CAR-T approval, 96% manufacturing success rate 30-Jul-2020 By Ben Hargreaves Kite becomes the first company to have two approved CAR-T treatments, with its second targeting rare form of lymphoma.
Hired & Retired: Taking care of business 29-Jul-2020 By Ben Hargreaves The industry plumps for business acumen, as companies seek to turn drug candidates from pipeline prospects to approved products.
AZ bets billions on Daiichi’s ADC therapy 28-Jul-2020 By Ben Hargreaves AZ agrees deal with Daiichi to co-develop a treatment in oncology, as part of its ADC strategy.
BD receives order for 177m syringes from US and Canada 27-Jul-2020 By Ben Hargreaves US and Canadian governments enter deal for needles and syringes to deliver potential COVID-19 vaccine.
